These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 25372189

  • 1. Impact of dietary benzoic acid on treatment response in schizophrenia.
    Glue P, Gale C, Parnell W.
    JAMA Psychiatry; 2014 Nov; 71(11):1298-9. PubMed ID: 25372189
    [No Abstract] [Full Text] [Related]

  • 2. Impact of dietary benzoic acid on treatment response in schizophrenia--reply.
    Tsai GE.
    JAMA Psychiatry; 2014 Nov; 71(11):1299. PubMed ID: 25372191
    [No Abstract] [Full Text] [Related]

  • 3. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 4. Comments on 'The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia'.
    Hashimoto K.
    J Psychopharmacol; 2010 Jul; 24(7):1133-4. PubMed ID: 19939869
    [No Abstract] [Full Text] [Related]

  • 5. Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
    Matsuura A, Fujita Y, Iyo M, Hashimoto K.
    Acta Neuropsychiatr; 2015 Jun; 27(3):159-67. PubMed ID: 25648314
    [Abstract] [Full Text] [Related]

  • 6. Lack of Effect of Sodium Benzoate at Reported Clinical Therapeutic Concentration on d-Alanine Metabolism in Dogs.
    Popiolek M, Tierney B, Steyn SJ, DeVivo M.
    ACS Chem Neurosci; 2018 Nov 21; 9(11):2832-2837. PubMed ID: 29893546
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756.
    Howley E, Bestwick M, Fradley R, Harrison H, Leveridge M, Okada K, Fieldhouse C, Farnaby W, Canning H, Sykes AP, Merchant K, Hazel K, Kerr C, Kinsella N, Walsh L, Livermore DG, Hoffman I, Ellery J, Mitchell P, Patel T, Carlton M, Barnes M, Miller DJ.
    Neurochem Res; 2017 Nov 21; 42(11):3279-3288. PubMed ID: 28780732
    [Abstract] [Full Text] [Related]

  • 8. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY.
    World J Biol Psychiatry; 2017 Aug 21; 18(5):357-368. PubMed ID: 26691576
    [Abstract] [Full Text] [Related]

  • 9. Repurposing Drugs for Cognition in Schizophrenia.
    Yang YS, Marder SR, Green MF.
    Clin Pharmacol Ther; 2017 Feb 21; 101(2):191-193. PubMed ID: 27706797
    [Abstract] [Full Text] [Related]

  • 10. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
    Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, Lane HY.
    Biol Psychiatry; 2014 May 01; 75(9):678-85. PubMed ID: 24074637
    [Abstract] [Full Text] [Related]

  • 11. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.
    Green MF.
    Am J Psychiatry; 2007 Jul 01; 164(7):992-4. PubMed ID: 17606645
    [No Abstract] [Full Text] [Related]

  • 12. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW.
    Am J Psychiatry; 2006 Nov 01; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract] [Full Text] [Related]

  • 13. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW.
    Arch Gen Psychiatry; 2007 Jun 01; 64(6):631-2. PubMed ID: 17548745
    [No Abstract] [Full Text] [Related]

  • 14. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
    Williams M.
    Biochem Pharmacol; 2009 Dec 01; 78(11):1360-5. PubMed ID: 19591808
    [Abstract] [Full Text] [Related]

  • 15. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
    Purdon SE.
    J Psychiatry Neurosci; 2000 Mar 01; 25(2):108-16. PubMed ID: 10740984
    [No Abstract] [Full Text] [Related]

  • 16. The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.
    Abou El-Magd RM, Park HK, Kawazoe T, Iwana S, Ono K, Chung SP, Miyano M, Yorita K, Sakai T, Fukui K.
    J Psychopharmacol; 2010 Jul 01; 24(7):1055-67. PubMed ID: 19329549
    [Abstract] [Full Text] [Related]

  • 17. Food preservatives sodium benzoate and propionic acid and colorant curcumin suppress Th1-type immune response in vitro.
    Maier E, Kurz K, Jenny M, Schennach H, Ueberall F, Fuchs D.
    Food Chem Toxicol; 2010 Jul 01; 48(7):1950-6. PubMed ID: 20435078
    [Abstract] [Full Text] [Related]

  • 18. Sodium benzoate attenuates D-serine induced nephrotoxicity in the rat.
    Williams RE, Lock EA.
    Toxicology; 2005 Feb 01; 207(1):35-48. PubMed ID: 15590120
    [Abstract] [Full Text] [Related]

  • 19. Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
    Croarkin PE, Daskalakis ZJ.
    J Am Acad Child Adolesc Psychiatry; 2012 Sep 01; 51(9):949-51. PubMed ID: 22917209
    [No Abstract] [Full Text] [Related]

  • 20. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
    Addington J, Addington D.
    Can J Psychiatry; 1997 Nov 01; 42(9):983. PubMed ID: 9429073
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.